ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy for Metachromatic Leukodystrophy (TIGET-MLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01560182
Recruitment Status : Active, not recruiting
First Posted : March 22, 2012
Last Update Posted : March 24, 2017
Sponsor:
Collaborator:
Fondazione Telethon
Information provided by (Responsible Party):
GlaxoSmithKline

March 16, 2012
March 22, 2012
March 24, 2017
May 2010
April 2023   (Final data collection date for primary outcome measure)
  • Conditioning regimen-related safety [ Time Frame: at +60 days after transplantation ]
    The absence of engraftment failure or delayed hematopoietic reconstitution (prolonged
  • Conditioning regimen-related toxicity [ Time Frame: 3 years ]
    The absence of regimen related toxicity, as determined by a surveillance of clinical (NCI >2
  • The short-term safety and tolerability of lentiviral-transduced cell infusion [ Time Frame: 48 hours after transplant ]
    It will be evaluated on the basis of adverse events reporting and monitoring of the systemic
  • Improvement of GMFM score [ Time Frame: 24 months after treatment ]
    An improvement of 10% of the total GMFM score in treated patients, when compared to the
  • Increase of residual ARSA activity [ Time Frame: 24 months after treatment ]
    A significant (≥ 2 SD) increase of residual ARSA activity as compared to pretreatment
  • The long-term safety of lentiviral-transduced cell infusion [ Time Frame: 24 months after the treatment ]
    Absence of Replication Competent Lentivirus (RCL): ELISA for HIV p24 antigen
  • Conditioning regimen-related safety [ Time Frame: at +60 days after transplantation ]
    The absence of engraftment failure or delayed hematopoietic reconstitution (prolonged aplasia), defined as Absolute Neutrophil Count (ANC)<500/μl with no evidence of BM recovery, requiring cellular back-up administration.
  • Conditioning regimen-related toxicity [ Time Frame: 3 years ]
    The absence of regimen related toxicity, as determined by a surveillance of clinical (NCI >2) and laboratory (NCI >3) parameters.
  • The short-term safety and tolerability of lentiviral-transduced cell infusion [ Time Frame: 48 hours after transplant ]
    It will be evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion (fever, tachycardia, nausea and vomiting, joint pain, skin rash).
  • Improvement of GMFM score [ Time Frame: 24 months after treatment ]
    An improvement of 10% of the total GMFM score in treated patients, when compared to the GMFM scores in control MLD population. GMFM is a clinically relevant endpoint being a direct measure of motor impairment and there is a causal relationship between the potential beneficial outcome measured with the GMFM and the treatment, being motor impairment consequent to the involvement of both CNS and PNS, and less influenced by other variables. A 10% modification of the total GMFM score is as a clinically relevant change according to the experience of therapists in children with cerebral palsy.
  • Increase of residual ARSA activity [ Time Frame: 24 months after treatment ]
    A significant (≥ 2 SD) increase of residual ARSA activity as compared to pretreatment values, measured in PBMC and/or BM progenitors.
  • The long-term safety of lentiviral-transduced cell infusion [ Time Frame: 24 months after the treatment ]
    • Absence of Replication Competent Lentivirus (RCL): ELISA for HIV p24 antigen (plasma) and DNA PCR for VSV-G env (cells). If the test will result positive, further tests by Q-RT-PCR for HIV-gag/pol RNA in plasma and additional investigations (confirmatory RCL culture tests) will be performed as appropriate.
    • Absence of Abnormal Clonal Proliferation (ACP). Abnormal hematopoietic clonal expansion will be monitored by clinical and laboratory surveillance, repertoire study, and bone marrow examination.
Complete list of historical versions of study NCT01560182 on ClinicalTrials.gov Archive Site
  • The absence of immune responses against the transgene [ Time Frame: every three months for the first year, then once a year. ]
    Even if we do not expect immune responses against the functional ARSA enzyme,
  • Improvement in the NCV Index for ENG and in the total score for MR [ Time Frame: 24 months after treatment ]
    An improvement in the NCV Index for ENG and in the total score for MR of ≥ 2 SD, when
  • Transduced cell engraftment [ Time Frame: 12 months after treatment ]
    Transduced cell engraftment above 4% in PBMCs and CD34+ progenitors in BM
  • IQ measurement above 55 [ Time Frame: 24, 30 and 36 months after treatment ]
    The measurement of an IQ above 55 (threshold for severe disability) at neuro-psychological
  • The absence of immune responses against the transgene [ Time Frame: every three months for the first year, then once a year. ]
    Even if we do not expect immune responses against the functional ARSA enzyme, according to our preclinical data and having most of MLD patients residual enzymatic activity, treated patients will be monitored for antibodies anti-ARSA (immunoblot analyses).
  • Improvement in the NCV Index for ENG and in the total score for MR [ Time Frame: 24 months after treatment. ]
    An improvement in the NCV Index for ENG and in the total score for MR of ≥ 2 SD, when compared to the scores observed in the historical control MLD population. ENG and MR were validated as informative quantitative instrumental read outs during our natural history study.
  • Transduced cell engraftment [ Time Frame: 12 months after treatment ]
    Transduced cell engraftment above 4% in PBMCs and CD34+ progenitors in BM (determined as VCN/cell ≥0.04 at quantitative PCR, equivalent to 4% assuming a VCN of 1). This value is based on clinical experience in other gene therapy trials, which has demonstrated 4% average long-term engraftment of autologous hematopoietic stem/progenitor cells transduced with onco-retroviral vectors in the bone marrow of pediatric patients suffering from immunodeficiency (ADA-SCID) and receiving reduced intensity, non-myeloablative conditioning.
Not Provided
Not Provided
 
Gene Therapy for Metachromatic Leukodystrophy
A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy
This is a phase I/II protocol aiming at the assessment of the safety and efficacy of ARSA gene transfer into hematopoietic stem/progenitor cells for the treatment of Metachromatic Leukodystrophy.

Metachromatic Leukodystrophy (MLD) is an autosomal recessive Lysosomal Storage Disorder (LSD) characterized by severe and progressive dysmyelination affecting the central and peripheral nervous system.

Hematopoietic cell transplantation (HCT) is ineffective in ameliorating patients' phenotype or delaying disease evolution. No evidences of efficacy of enzyme replacement strategies are available at the moment. Transplantation of genetically corrected autologous hematopoietic stem cells (HSC) could represent a novel and potentially efficacious treatment for MLD patients.

We are conducting a gene therapy clinical trial based on autologous HSC and advanced generation lentiviral vectors (LV) for patients affected by the most severe, early onset forms of the disease, based on our preclinical efficacy and safety data and on the experience we acquired from the treatment of Adenosine deaminase deficiency (ADA-SCID) patients by a similar approach. Our general goal is to demonstrate safety and efficacy of this gene therapy approach in MLD patients. We have developed and tested a clinically applicable LV containing the ARSA cDNA controlled by a constitutive eukaryotic promoter sequence. Preclinical studies aimed at assessing efficacy and safety of ARSA gene transfer using the selected vector have been conducted in the murine model of the disease and in progenitors and mature hematopoietic cells from MLD patients. The following results were obtained:

  1. efficient ARSA gene transfer;
  2. long term in vitro and in vivo multilineage ARSA expression;
  3. ability to prevent and correct neurological disease manifestations;
  4. good tolerance and long-term safety of the treatment in the animal model.

We expect to treat 20 patients, selected according to disease severity and clinical features. A myeloablative conditioning regimen based on iv Busulfan will be administered to the patients to enable engraftment of the transduced stem/progenitor cells in the bone marrow and enhance CNS microglia/macrophage repopulation by the transduced cell progeny. An efficient transduction protocol based on LVs has been optimized to guarantee abundant ARSA expression in the transduced patients' HSC and their progeny. In the treated patients, we will study the short-term and long-term safety of the administration of the autologous transduced HSC, their long-term engraftment, the expression of vector-derived ARSA, and the ability of the transduced cells to provide a clinical benefit to the patients. The treated patients will be followed for 3 years and thereafter monitored for the safety of gene therapy for additional 5 years. If successful, this study will provide key results on the safety and efficacy of gene therapy for MLD patients.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lysosomal Storage Disease
Genetic: Autologous CD34+ stem cells transduced with ARSA encoding lentiviral vector
Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA under the control of the human phosphoglyceratekinase (PGK) promoter. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
14
8
April 2023
April 2023   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pre-symptomatic late infantile patients
  • Pre- or early-symptomatic early juvenile patients (IQ > 70 and ability to walk independently for >10 steps)
  • Parental/guardian/patient signed informed consent.

Exclusion Criteria:

  • HIV RNA and/or HCV RNA and/or HBV DNA positive patients
  • Patients affected by neoplastic diseases
  • Patients with cytogenetic alterations typical of MDS/AML
  • Patients with end-organ functions or any other severe disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • Patients enrolled in other trials.
  • Patient who underwent allogeneic hematopoietic stem cell transplantation in the previous six months.
  • Patient who underwent allogenic hematopoietic stem cell transplantation with evidence of residual cells of donor origin.
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01560182
201222
Eudract 2009-017349-77 ( Other Identifier: IRCCS San Raffaele )
No
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Fondazione Telethon
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP